The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will ...
OSE Immunotherapeutics and the University of Kiel’s research teams demonstrated that using OSE-127 to target IL-7R is an efficient approach for BCP-ALL immunotherapy and may be particularly beneficial ...
CoVepiT is generated using OSE's proprietary Memopi® technology which has been validated for both safety and efficacy through the step-1 of Phase 3 clinical phase of neoepitope vaccine Tedopi® in ...
NANTES, France, June 12, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173);(Mnémo:OSE) today announced that the Company has entered into a multi-year research collaboration on ...
OSE Immunotherapeutics and Memorial Sloan Kettering Cancer Center (MSK) signed a multiyear agreement to support ongoing research with the French firm’s humanized monoclonal antibody (mAb) OSE-703 ...
KVH Co. Ltd., a leader in IT and Communications in Japan announced today that "KVH Proximity Hosting Service" had been selected by the Osaka Securities Exchange (OSE) as the connectivity service for ...
NANTES, France, Dec. 13, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first preclinical data on anti-leukemic efficacy of anti-IL-7 receptor ...
At the 2021 American Society of Hematology (ASH) Annual Meeting Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) presented the first preclinical data on ...
NANTES, France, Dec. 13, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first preclinical data on anti-leukemic efficacy of anti-IL-7 receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback